BLLN stock forecast, quote, news & analysis
BillionToOne Inc is a molecular diagnostics company... Show more
BillionToOne (BLLN) Stock Analysis: Rapid Growth Meets Insider-Selling Headwinds
Key Takeaways
- BillionToOne (BLLN) shares have pulled back modestly over the trailing month, moving from roughly $106 in mid-September to around $103, a decline of about 2%–3%.
- The pullback follows a sharp earlier rally to record highs, with insider sales and flat full-year guidance weighing on sentiment more than any deterioration in fundamentals.
- Revenue grew 64% year over year to $109.4 million in Q2 2026, driven by 56% growth in prenatal and 176% growth in oncology.
- The company achieved GAAP operating income of $5.5 million and held approximately $549 million in cash at the end of Q2 2026.
- Third-quarter 2026 results are scheduled for release after the market close on November 4, 2026.
Current Market Snapshot
BillionToOne shares have traded in a volatile range since the company's November 2025 initial public offering. After climbing sharply through September and reaching record levels, the stock has consolidated near the $100 mark. The company's market capitalization has hovered around $4.5 billion, and its 52-week range spans from a low near $66 to a high around $138.70. The recent dip reflects a reassessment of valuation following insider stock sales and management's decision to keep full-year revenue guidance unchanged, rather than any broad-based sector weakness. With a relatively short public trading history, BLLN remains sensitive to news flow, reimbursement headlines, and analyst estimate revisions.
BillionToOne (BLLN) Business Overview and Competitive Position
BillionToOne is a Menlo Park, California-based precision diagnostics company that quantifies biology to build molecular diagnostics. Its proprietary Quantitative Counting Templates (QCT) molecular counting platform detects and measures DNA molecules at the single-molecule level, a capability the company applies across two major markets: non-invasive prenatal testing and liquid biopsy for oncology.
In prenatal screening, the company's UNITY franchise includes UNITY Complete, UNITY Fetal Risk Screen, UNITY Aneuploidy Screen, and fetal antigen tests, along with UNITY Confirm, a non-invasive confirmation assay for high-risk pregnancies launched in May 2026. In oncology, the Northstar portfolio features Northstar Select for therapy selection, Northstar Response for treatment monitoring, and related add-on applications. The company competes in a fast-growing diagnostics market where test volume, average selling price, and payer coverage are key drivers, and it differentiates itself through single-molecule sensitivity and a rapidly expanding test menu.
Recent Developments Driving BLLN
Several verified developments have shaped investor sentiment toward BLLN in recent weeks. On the operational side, the company reported strong second-quarter results, with total revenue rising 64% year over year to $109.4 million. Prenatal revenue increased 56% to $95.8 million, while oncology revenue surged 176% to $13.7 million. Gross margin reached 70.5%, and the company generated positive GAAP operating income and free cash flow.
However, the stock's momentum has been tempered by a wave of insider selling. The chairman and CEO sold shares worth approximately $1.56 million under a pre-arranged Rule 10b5-1 trading plan, with additional shares sold by the CEO's spouse. Other executives, including the chief technology officer and a senior vice president, also reported sales. While such transactions are common following a significant run-up in a newly public company and do not necessarily signal a negative outlook, the concentration of selling contributed to a pullback from the stock's highs.
On the analyst front, coverage has been generally constructive. Guggenheim raised its price target on BLLN to $128 from $125 while maintaining a Buy rating, and Canaccord Genuity initiated coverage with a Buy rating and a $120 price target. The company has also confirmed it will report third-quarter 2026 results on November 4, 2026, which represents the next major catalyst for the stock.
Trending AI Robots
For investors and traders looking to complement their own research with systematic, data-driven approaches, Tickeron's Trending AI Robots page offers a curated view of AI-powered trading strategies. Tickeron hosts hundreds of AI trading bots that monitor thousands of tickers, but only the top-performing and most relevant bots are featured in this section. These bots vary in strategy, holding timeframe, and performance metrics, allowing users to explore different approaches to the market. The page provides a convenient way to discover automated strategies that align with different risk profiles and trading styles.
2026 Outlook and What Investors Should Watch
Looking ahead, the primary near-term catalyst for BLLN is the third-quarter earnings report scheduled for November 4, 2026. Investors will be watching for updates on test volume growth, average selling price trends, and whether management adjusts its full-year 2026 revenue guidance of $450 million to $465 million. On the oncology side, potential MolDX coverage decisions for Northstar Response and the planned launch of a tumor-naive minimal residual disease test before year-end represent important milestones.
Other factors to monitor include gross margin sustainability as the oncology mix grows, the pace of health-system integrations, and reimbursement dynamics with national payers. The company has also noted that more than $10 million in claims remained pending in-network implementation, an item that could influence future revenue and cash collections. As with all high-growth diagnostics companies, any slowdown in test adoption, delays in payer coverage, or sustained insider selling could affect investor sentiment, while continued volume and revenue growth would support the underlying investment thesis.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Momentum Indicator for BLLN turns positive, indicating new upward trend
BLLN saw its Momentum Indicator move above the 0 level on October 20, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 20 similar instances where the indicator turned positive. In 19 of the 20 cases, the stock moved higher in the following days. The odds of a move higher are at 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for BLLN just turned positive on October 21, 2026. Looking at past instances where BLLN's MACD turned positive, the stock continued to rise in 10 of 10 cases over the following month. The odds of a continued upward trend are 90%.
BLLN moved above its 50-day moving average on October 19, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for BLLN crossed bullishly above the 50-day moving average on October 26, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 1 of 1 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 90%.
Following a +5.85% 3-day Advance, the price is estimated to grow further. Considering data from situations where BLLN advanced for three days, in 47 of 53 cases, the price rose further within the following month. The odds of a continued upward trend are 89%.
Bearish Trend Analysis
The 10-day RSI Indicator for BLLN moved out of overbought territory on September 28, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 5 similar instances where the indicator moved out of overbought territory. In 4 of the 5 cases, the stock moved lower in the following days. This puts the odds of a move lower at 80%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 7 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BLLN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 80%.
BLLN broke above its upper Bollinger Band on October 26, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for BLLN entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is 43 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 49 (best 1 - 100 worst), indicating fairly steady price growth. BLLN’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 88 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (9.961) is normal, around the industry mean (67.473). BLLN has a moderately high P/E Ratio (135.765) as compared to the industry average of (2.957). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.473). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (12.195) is also within normal values, averaging (9.775).
The Tickeron PE Growth Rating for this company is 95 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BLLN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 85, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry MedicalSpecialties